Featured Mind map
Understanding Polycystic Ovary Syndrome (PCOS)
Polycystic Ovary Syndrome (PCOS) is a complex endocrine disorder affecting women of reproductive age. It is characterized by chronic hyper-androgenic anovulation and metabolic derangements, particularly involving insulin metabolism. Symptoms like irregular periods, excess androgen, and polycystic ovaries can vary and evolve, often having familial links and diverse inherited aspects.
Key Takeaways
PCOS involves hormonal imbalance, anovulation, and metabolic issues.
Diagnosis requires two of three criteria: irregular periods, hyperandrogenism, or polycystic ovaries.
Insulin resistance and obesity significantly impact PCOS severity.
Long-term risks include diabetes, cardiovascular disease, and endometrial cancer.
Management focuses on lifestyle, medication, and symptom-specific treatments.
What is Polycystic Ovary Syndrome (PCOS)?
Polycystic Ovary Syndrome (PCOS) is a complex endocrine disorder. It features chronic hyper-androgenic anovulation and metabolic derangements, especially involving insulin. Symptoms are heterogeneous, familial, and impact reproductive and metabolic health significantly, often changing over time due to inherited aspects.
- Chronic hyper-androgenic anovulation
- Associated with metabolic derangement
- Heterogeneity of symptoms and signs
- Familial
- Differentially inherited aspects
How was Polycystic Ovary Syndrome (PCOS) first recognized?
Stein and Leventhal first described PCOS in 1935, noting amenorrhea, hirsutism, infertility, and enlarged ovaries. Their "Stein-Leventhal syndrome" involved wedge resection, leading to resumed menses. Later, McArthur observed elevated LH, and Kahn & Burghenet linked PCOS to insulin resistance, advancing understanding of its pathophysiology.
- 1935: Stein & Leventhal
- First described symptom complex
- Associated with anovulation
- 7 patients (4 obese)
- Symptoms: amenorrhea, hirsutism, infertility, enlarged polycystic ovaries
- Bilateral wedge resection results
- Removed 1/2 to 3/4 of each ovary
- All 7 resumed regular menses
- 2 became pregnant
- Reasoned thickened tunica prevented follicles from reaching surface
- Called "The Stein-Leventhal syndrome"
- 1958: McArthur
- Observed elevated LH levels
- Kahn & Burghenet a1
- Discovered association of PCOS & insulin resistance
What are the diagnostic criteria for PCOS according to the Rotterdam Consensus?
The Rotterdam ESHRE 2003 Consensus refined PCOS diagnosis. It requires two of three criteria: oligo- or anovulation, hyperandrogenism (clinical/biochemical), or polycystic ovaries on ultrasound (12+ follicles or >10 cm³ volume). Other etiologies like adrenal hyperplasia, hyperprolactinemia, or Cushing's syndrome must be excluded for accurate diagnosis.
- Refined definition agreed
- Presence of 2/3 criteria
- Oligo- and/or anovulation
- Hyperandrogenism (clinical and/or biochemical)
- Polycystic ovaries on ultrasound
- Ovary with 12+ follicles (2-9mm diameter)
- OR increased ovarian volume (>10 cm^3)
- Exclusion of other etiologies
- Late onset adrenal hyperplasia
- Hyperprolactinemia
- Acromegaly
- Androgen producing neoplasms
- Cushing's syndrome
How common is Polycystic Ovary Syndrome (PCOS)?
PCOS affects 5-10% of reproductive-aged women, making it a frequent hormonal imbalance. Notably, 20-30% of asymptomatic females may show polycystic ovaries on ultrasound without meeting full diagnostic criteria. Comprehensive clinical assessment, beyond ovarian morphology, is crucial for accurate diagnosis and management.
- 5-10% in women of reproductive age
- 20-30% of asymptomatic females have polycystic ovaries
What are the common clinical features of PCOS?
PCOS presents with diverse clinical features. Hyperandrogenism causes acne, hirsutism, and alopecia. Menstrual disturbances, from irregular to absent periods, reflect anovulation. Infertility is common due to ovulatory dysfunction. Obesity is frequently associated, exacerbating symptoms and metabolic complications, guiding diagnosis.
- Hyperandrogenism
- Acne
- Hirsutism
- Alopecia
- Menstrual disturbances
- Infertility
- Obesity
What are the underlying pathophysiological and metabolic features of PCOS?
PCOS pathophysiology involves dysregulated androgen secretion, driven by increased LH, insulin/IGF, and ovarian androgen production. This often causes an ovarian steroidogenesis block. Consequences include hyperandrogenaemia (hirsutism, acne) and follicular atresia, leading to anovulation and infertility, which are key to its clinical presentation.
- Dysregulation of androgen secretion
- Increased Lutenizing hormone
- Increased Insulin/Insulin-like growth factor
- Increased Extraovarian androgen
- Increased Intraovarian androgen
- Ovarian steroidogenesis block
- Consequences
- Hyperandrogenaemia
- Follicular atresia
How does PCOS affect hypothalamic and pituitary function?
In PCOS, hypothalamic and pituitary function is altered. Increased LH secretion with low/normal FSH leads to an elevated LH:FSH ratio. Enhanced LH pulse frequency, amplitude, and responses to GnRH create a "steady state" of gonadotropin release, ultimately causing chronic anovulation, a hallmark of the syndrome.
- Increased LH secretion (low/normal FSH)
- Increased LH pulse frequency & amplitude
- Normal or low FSH concentrations
- Elevated LH:FSH ratio
- Increased LH responses to GnRH
- Leads to "steady state" of FSH & LH release
- Ultimately to anovulation
What role does androgen secretion play in PCOS?
Androgen secretion is central to PCOS, with 50-90% of women having elevated serum androgens (testosterone, androstenedione, DHEA-S). Testosterone's biological activity depends on its free fraction, determined by SHBG. Estrogens increase SHBG, while androgens and insulin decrease it, increasing free testosterone and exacerbating hyperandrogenic symptoms.
- 50-90% women with PCOS have elevated serum androgens
- Testosterone (T)
- Androstenedione (A)
- Dehydroepiandrosterone (DHEA)
- Dehydroepiandrosterone Sulfate (DHEA-S)
- Biological activity of testosterone
- Most potent circulating endogenous androgen
- Determined by binding to Sex Hormone-Binding Globulin (SHBG)
- Free fraction of testosterone is biologically active
- Factors affecting SHBG synthesis
- Estrogens increase SHBG
- Androgens & Insulin decrease SHBG
- Increases free serum testosterone
Why is ovarian androgen secretion increased in PCOS?
Increased ovarian androgen secretion in PCOS is primarily due to elevated serum Luteinizing Hormone (LH) levels. LH excessively stimulates ovarian theca cells to produce androgens. Decreased Follicle-Stimulating Hormone (FSH) stimulation of granulosa cells, which normally convert androgens to estrogens, exacerbates this, promoting hyperandrogenism.
- Elevated serum LH levels may explain increased ovarian androgen secretion
- Androgen synthesis increased by excess LH stimulation of theca cells
- Exacerbated by decreased FSH stimulation of granulosa cells
How does obesity relate to Polycystic Ovary Syndrome (PCOS)?
Obesity (BMI > 28) is frequently associated with PCOS, impacting severity and health risks. Obese individuals face increased incidence of stroke, heart disease, and diabetes. Obesity also links to lower SHBG concentrations, increasing free testosterone and worsening hyperandrogenic symptoms. It has both a separate and synergistic relationship with PCOS.
- Defined as BMI > 28
- Increased incidence of associated morbidities
- Stroke
- Ischemic heart disease
- Diabetes (3-4x greater)
- Associated with lower SHBG concentrations
- Affects circulating levels of free testosterone
- Separate & synergistic relation with PCOS
What is the role of insulin resistance in PCOS pathogenesis?
Insulin resistance is pivotal in PCOS pathogenesis, marked by hyperinsulinemia and decreased peripheral insulin sensitivity. Hyperinsulinemia inhibits hepatic SHBG and IGFBP-1 production, increasing biologically available free testosterone. Ovaries remain sensitive to insulin, stimulating theca androgen production. This directly contributes to elevated ovarian androgens and active hormones, driving PCOS symptoms.
- Basal & glucose-stimulated hyperinsulinemia
- Decreased peripheral insulin sensitivity
- Pivotal in PCOS pathogenesis
- Mechanism uncertain
- Post-receptor defect in adipose tissue identified
- Effects of Hyperinsulinemia
- Insulin inhibits hepatic SHBG & IGFBP-1 production
- Increased biologically available free testosterone
- Ovary remains sensitive to insulin
- Insulin & IGF-I stimulate theca androgen production
- Increased insulin resistance leads to:
- Increased ovarian androgens
- Increased proportion of free (active) hormone
How is Metabolic Syndrome connected to PCOS?
Metabolic Syndrome, or Syndrome X, is closely linked to PCOS, increasing risks for heart disease, stroke, and type 2 diabetes. It comprises insulin resistance, hyperinsulinemia, abdominal obesity, dyslipidemia, and hypertension. This syndrome is directly involved in Type II Diabetes pathogenesis. Recognizing and managing metabolic syndrome is crucial for individuals with PCOS.
- Consists of:
- Insulin resistance
- Compensatory hyperinsulinemia
- Obesity (abdominal/visceral)
- Dyslipidemia (high triglycerides/low HDL)
- Hypertension
- Directly involved in Type II Diabetes pathogenesis
- Risk Factor Cut-offs
- Abdominal obesity: >88 cm (>35 inches)
- Triglycerides: >150 mg/dl
- HDL-C: <50 mg/dl
- Blood pressure: >130/85 mmHg
- Fasting glucose: 110 +/- 126 mg/dl
- 2h glucose from OGTT: 140 +/- 199 mg/dl
What is HAIR-AN Syndrome and its significance in PCOS?
HAIR-AN Syndrome is an association in some PCOS individuals, characterized by Hyperandrogenism, Insulin Resistance, and Acanthosis Nigricans. Acanthosis Nigricans, dry, dark skin patches typically in armpits, neck, and groin, signals severe insulin resistance. Its presence indicates pronounced metabolic derangement, guiding more aggressive management strategies for insulin sensitivity.
- Association of Hyperandrogenism
- Insulin Resistance
- Acanthosis Nigricans
- Dry, dark patches of skin
- Usually appear in armpits, neck, groin
- Considered sign of insulin resistance
What investigations are used to diagnose PCOS?
Diagnosing PCOS involves clinical assessment and specific investigations. Pelvic ultrasound, especially transvaginal, is crucial for assessing ovarian morphology. It typically reveals small antral follicles peripherally, a "Pearl-Necklace" appearance, and increased stromal thickness. Ultrasound findings must be interpreted with clinical symptoms and hormonal profiles for comprehensive diagnosis.
- Pelvic Ultrasound (Transvaginal)
- Assess ovarian morphology
- Small antral follicles peripherally distributed
- Increased stromal thickness
- Giving "Pearl-Necklace" appearance
What hormonal changes are typically seen in PCOS?
The PCOS hormonal profile shows increased androgens (T, A, DHEA-S), LH (>10 IUI/ml), estrogen (estrane>estradiol), insulin (>10 mIU/L), and sometimes prolactin, LDL/cholesterol, and triglycerides. Decreased hormones include FSH, progesterone, SHBG, HDL, and apoprotein A. Total testosterone is adequate for screening.
- Hormones Increased
- Androgens (Testosterone, Androstenedione, DHEA-S)
- LH (>10 IUI/ml)
- Estrogen (Estrone > Estradiol)
- Insulin (>10 mIU/L)
- Prolactin (in some patients)
- LDL/Cholesterol & Triglycerides
- Hormones Decreased
- FSH
- Progesterone (anovulation)
- SHBG
- HDL & Apoprotein A
- Note on Hormonal Measures
- Total testosterone (N=0.3-1 ng/ml) adequate for general screening
- Estradiol measurement unhelpful (estrogenization confirmed by endometrial assessment)
- LH & FSH best measured days 1-3 of menstrual bleed
- Thyroid functions & prolactin measured for oligo/amenorrhea
- Fasting insulin not routinely measured
- Insulin resistance assessed by fasting glucose:fasting insulin ratio (N=<4.5) & HOMA/IR
What are the long-term health consequences of PCOS?
PCOS carries significant long-term health consequences. Women, especially if obese, face increased risk of Type II Diabetes. Cardiovascular risk is elevated due to obesity, hypertension, hyperandrogenism, hyperinsulinemia, and abnormal lipids, increasing atherosclerotic conditions and myocardial infarction risk. Endometrial hyperplasia risk also exists.
- PCOS & Risk of Type II Diabetes
- Increased risk, particularly if obese
- PCOS & Cardiovascular Risk
- Elevated cardiovascular risk factors
- Obesity
- Hypertension
- Hyperandrogenism
- Hyperinsulinemia
- Abnormal lipid profile
- Increased risk of atherosclerotic conditions
- Increased risk of myocardial infarction
- PCOS & Cancer
- Oligo- & amenorrheic women may develop endometrial hyperplasia
- Later carcinoma
- Progestogen treatment (every 3-4 months) recommended
- PCOS & Pregnancy
- Increased risk of gestational diabetes
What are the primary treatment approaches for PCOS?
PCOS treatment is multifaceted, managing symptoms and reducing long-term risks. Lifestyle changes (exercise, weight control) are foundational, often restoring ovulation and reducing diabetes risk. Insulin-sensitizing agents (Metformin) reduce insulin resistance. OCPs manage menstrual cycles. Ovulation induction (Clomiphene Citrate) and antiandrogens (Spironolactone) address specific concerns.
- Lifestyle Changes
- Exercise & Weight Control
- Resumption of ovulation & increased fertility (anovulatory obese women)
- Reduced likelihood of Type II Diabetes
- Insulin Sensitizing Agents
- Metformin & Troglitazone
- Reduce insulin resistance
- Reduce diabetes & metabolic sequelae risk
- Reduce fasting serum insulin, androgen, LH
- Increase SHBG
- Restore regular menstrual cycles & ovulation
- Combined Oral Contraceptive Pills (OCPs)
- For amenorrheic women (risk of endometrial hyperplasia)
- Controls menstrual cycle
- Results in artificial cycle & regular shedding of endometrium
- Progestin
- Medroxyprogesterone acetate or dydrogesterone
- 12 days every 1-3 months to induce withdrawal bleed
- Encourage weight loss
- Induction of Ovulation
- Anti-estrogens (Clomiphene Citrate, Tamoxifen)
- Aromatase inhibitors (Letrozole)
- Clomiphene successful in >80% ovulation
- Pregnancy only occurs in ~50%
- Second-line therapies (after 6-12 months)
- Gonadotropins
- Laparoscopic ovarian drilling
- Antiandrogens for Hirsutism
- Cyproterone acetate (in Diane pill)
- Achieves cycle regulation & hirsutism treatment
- Spironolactone (diuretic) useful in low doses
How is a typical case of PCOS managed?
Managing PCOS involves a tailored approach based on primary concerns. OCPs regulate irregular bleeding and protect the endometrium. Hirsutism is managed with OCPs or Spironolactone. Infertility requires ovulation induction therapies. For general health risks, particularly related to insulin resistance and metabolic syndrome, Metformin is a common intervention.
- PCOS (Chronic anovulation & androgen excess)
- Irregular bleeding
- OCPs
- Hirsutism
- OCPs/Spironolactone
- Infertility
- Ovulation induction
- General health risks
- Metformin
Frequently Asked Questions
What are the main diagnostic criteria for PCOS?
PCOS is diagnosed if you have two of three: irregular periods/anovulation, clinical/biochemical hyperandrogenism, or polycystic ovaries on ultrasound, after excluding other conditions.
How does insulin resistance affect PCOS?
Insulin resistance is central to PCOS, leading to higher insulin levels. This increases free testosterone and stimulates ovarian androgen production, worsening symptoms like hyperandrogenism and anovulation.
What are the long-term health risks associated with PCOS?
Long-term risks include increased chances of Type II Diabetes, cardiovascular disease due to metabolic factors, and endometrial hyperplasia or cancer if periods are consistently irregular.
Can lifestyle changes help manage PCOS?
Yes, lifestyle changes like exercise and weight control are foundational. They can help restore ovulation, improve fertility, reduce insulin resistance, and lower the risk of Type II Diabetes.
What are common treatments for PCOS symptoms?
Treatments vary by symptom: OCPs for irregular periods and hirsutism, antiandrogens for hirsutism, ovulation induction for infertility, and Metformin for insulin resistance and metabolic risks.
Related Mind Maps
View AllNo Related Mind Maps Found
We couldn't find any related mind maps at the moment. Check back later or explore our other content.
Explore Mind Maps
